Single-Shot ChAd3-MARV Vaccine in Modified Formulation Buffer Shows 100% Protection of NHPs.
Marburg virus
adenovirus
crab-eating macaque
cynomolgus macaque
filovirus
glycoprotein
nonhuman primate
vaccine
Journal
Vaccines
ISSN: 2076-393X
Titre abrégé: Vaccines (Basel)
Pays: Switzerland
ID NLM: 101629355
Informations de publication
Date de publication:
15 Nov 2022
15 Nov 2022
Historique:
received:
30
09
2022
revised:
01
11
2022
accepted:
03
11
2022
entrez:
24
11
2022
pubmed:
25
11
2022
medline:
25
11
2022
Statut:
epublish
Résumé
Marburg virus (MARV) is a virus of high human consequence with a case fatality rate of 24-88%. The global health and national security risks posed by Marburg virus disease (MVD) underscore the compelling need for a prophylactic vaccine, but no candidate has yet reached regulatory approval. Here, we evaluate a replication-defective chimpanzee adenovirus type 3 (ChAd3)-vectored MARV Angola glycoprotein (GP)-expressing vaccine against lethal MARV challenge in macaques. The ChAd3 platform has previously been reported to protect against the MARV-related viruses, Ebola virus (EBOV) and Sudan virus (SUDV), and MARV itself in macaques, with immunogenicity demonstrated in macaques and humans. In this study, we present data showing 100% protection against MARV Angola challenge (versus 0% control survival) and associated production of GP-specific IgGs generated by the ChAd3-MARV vaccine following a single dose of 1 × 10
Identifiants
pubmed: 36423030
pii: vaccines10111935
doi: 10.3390/vaccines10111935
pmc: PMC9694189
pii:
doi:
Types de publication
Journal Article
Langues
eng
Subventions
Organisme : NCRR NIH HHS
ID : C06 RR012087
Pays : United States
Organisme : NIH HHS
ID : P51 OD011133
Pays : United States
Organisme : ODCDC CDC HHS
ID : P51 OD011133
Pays : United States
Références
PLoS One. 2019 Apr 18;14(4):e0215457
pubmed: 30998735
PLoS One. 2014 Apr 23;9(4):e94355
pubmed: 24759889
PLoS Pathog. 2022 Oct 13;18(10):e1010805
pubmed: 36227853
PLoS Negl Trop Dis. 2021 Mar 29;15(3):e0009300
pubmed: 33780452
Microorganisms. 2021 Feb 26;9(3):
pubmed: 33652589
Nat Rev Microbiol. 2019 May;17(5):261-263
pubmed: 30926957
NPJ Vaccines. 2020 Dec 17;5(1):112
pubmed: 33335092
Vaccines (Basel). 2022 Aug 14;10(8):
pubmed: 36016203
Int J Infect Dis. 2020 Oct;99:233-242
pubmed: 32758690
Lancet. 2015 Apr 18;385(9977):1545-54
pubmed: 25540891
N Engl J Med. 2020 May 7;382(19):1832-1842
pubmed: 32441897
PLoS One. 2007 Aug 22;2(8):e764
pubmed: 17712412
Comp Med. 2017 Jun 1;67(3):253-262
pubmed: 28662754
Vaccines (Basel). 2022 Jul 29;10(8):
pubmed: 36016099
Emerg Infect Dis. 2020 Dec;26(12):3051-3055
pubmed: 33219802
J Virol. 2015 Jul;89(13):6773-81
pubmed: 25903348
Nat Med. 2014 Oct;20(10):1126-9
pubmed: 25194571
Cell. 2015 Feb 26;160(5):904-912
pubmed: 25723165
Viruses. 2018 Nov 21;10(11):
pubmed: 30469360
J Virol. 2015 Oct;89(19):9875-85
pubmed: 26202230
Front Immunol. 2021 Aug 18;12:703986
pubmed: 34484200
Virus Genes. 2017 Aug;53(4):501-515
pubmed: 28447193
J Infect Dis. 2019 Apr 8;219(8):1187-1197
pubmed: 30407513
J Virol. 2010 Oct;84(19):10386-94
pubmed: 20660192
N Engl J Med. 2017 Mar 9;376(10):928-938
pubmed: 25426834
mSphere. 2018 Jan 3;3(1):
pubmed: 29299527
J Virol. 2018 Jan 17;92(3):
pubmed: 29142131
Lancet Infect Dis. 2016 Jan;16(1):31-42
pubmed: 26546548
PLoS One. 2018 Feb 20;13(2):e0192312
pubmed: 29462200
Front Immunol. 2019 Jan 22;9:3071
pubmed: 30723475
Vaccines (Basel). 2021 Feb 25;9(3):
pubmed: 33668698
N Engl J Med. 2016 Apr 28;374(17):1635-46
pubmed: 25629663
Viruses. 2017 Oct 29;9(11):
pubmed: 29109373
Nat Med. 2011 Aug 21;17(9):1128-31
pubmed: 21857654
Lancet Infect Dis. 2016 Mar;16(3):311-20
pubmed: 26725450
J Virol. 2011 Aug;85(16):8188-96
pubmed: 21680524
Nat Microbiol. 2016 Aug 22;1(10):16142
pubmed: 27670117
J Clin Invest. 2020 Jan 2;130(1):539-551
pubmed: 31820871
J Immunol. 2013 Mar 15;190(6):2720-35
pubmed: 23390298
Zool Res. 2018 Jan 18;39(1):15-24
pubmed: 29511141
Dis Model Mech. 2009 Jan-Feb;2(1-2):12-7
pubmed: 19132113
Front Immunol. 2021 Oct 27;12:774026
pubmed: 34777392